Search
elranatamab-bcmm (Elrexfio)
Indications:
- treatment of adult patients with relapsed or refractory multiple myeloma
- patients who have received at >= 4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, & an anti-CD38 monoclonal Ab
Dosage:
- subcutananeous administration
- day 1: 12 mg (1st step-up dose)
- day 4: 32 mg (2nd step-up dose)
- day 8: 76 mg (first treatment dose)
- weekly dose: 76 mg through week 24
- biweekly dose: 76 mg week 25 & every 2 weeks thereafter (responders only)
* patients should be hospitalized for 48 hours after administration of the 1st step-up dose, & for 24 hours after administration of the 2nd step-up dose.
Adverse effects:
- >= 20%
- cytokine-release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, pyrexia
- laboratory abnormalities >=30%
- pancytopenia, anemia, leukopenia, lymphopenia, neutropenia, thrombocytopenia
Mechanism of action:
- bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
- binds to BCMA plasma cells, plasmablasts, & multiple myeloma cells & CD3 on T-cells leading to cytolysis of the BCMA-expressing cells
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Elrexfio - (elranatamab-bcmm) injection, for subcutaneous use
https://labeling.pfizer.com/ShowLabeling.aspx?id=19669